nach oben

Erschienen in:

01.12.2024 | Original Article

Safety and efficacy of radiotherapy combined with chemotherapy for recurrent metastatic renal pelvic and ureteral carcinoma

verfasst von: Ming-Zhu Liu, Xiao-Ying Li, Feng Lyu, Xian-Shu Gao, Jia-Yan Chen, Yan Gao, Mu Xie, Xue-Ying Ren, Ming-Wei Ma

Erschienen in: World Journal of Urology | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To retrospectively investigate the safety and efficacy of radiotherapy combined with chemotherapy for recurrent metastatic renal pelvic and ureteral carcinoma.

Methods

109 patients were enrolled in this study, including 44 patients in the radiochemotherapy group and 65 patients in the chemotherapy group. Propensity score matching (PSM) was used to balance the baseline characteristics of the two groups by 1:1 matching. Kaplan–Meier method was used to calculate PFS and OS. Cox regression model was used for multivariate analysis. The side effects were evaluated by CTCAE v5.0

Results

The median follow-up time was 14.5 months. Multivariate analysis showed that radiotherapy was a good independent prognostic factor for OS (HR: 0.327, 95% CI 0.157–0.680, P = 0.003). After matching, there were 40 patients in both groups, and the median PFS and OS in the radiochemotherapy group were longer than those in the chemotherapy group (PFS: 10.4 vs. 6.7 months, P = 0.035; OS: 43.5 vs. 18.8 months, P < 0.001). In addition, in the radiochemotherapy group, patients treated with radiotherapy before first-line chemotherapy failure had a longer PFS than those treated with radiotherapy after chemotherapy failure (median PFS: 15.7 vs. 6 months, P = 0.003). There was no significant difference in the incidence of grade 3–4 toxicities between the two groups (52.3% vs. 50.8%, P = 0.878).

Conclusion

For patients with recurrent metastatic renal pelvic and ureteral carcinoma, radiotherapy combined with chemotherapy is well tolerable and expected to bring long-term survival benefits, and the benefits of early interventional radiotherapy may be more obvious.

Rink M, Sjoberg D, Comploj E et al (2012) Risk of cancer-specific mortality following recurrence after radical nephroureterectomy. Ann Surg Oncol 19(13):4337–4344. https://doi.org/10.1245/s10434-012-2499-8CrossRefPubMedPubMedCentral

Bellmunt J, von der Maase H, Mead GM et al (2012) Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987. J Clin Oncol 30(10):1107–1113. https://doi.org/10.1200/JCO.2011.38.6979CrossRefPubMedPubMedCentral

Bamias A, Dafni U, Karadimou A et al (2013) Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). Ann Oncol 24(4):1011–1017. https://doi.org/10.1093/annonc/mds583CrossRefPubMed

Pham MN, Apolo AB, De Santis M et al (2017) Upper tract urothelial carcinoma topical issue 2016: treatment of metastatic cancer. World J Urol 35(3):367–378. https://doi.org/10.1007/s00345-016-1885-4CrossRefPubMed

Fradet Y, Bellmunt J, Vaughn DJ et al (2019) Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up. Ann Oncol 30(6):970–976. https://doi.org/10.1093/annonc/mdz127CrossRefPubMedPubMedCentral

Iwamoto H, Izumi K, Shimura Y et al (2016) Metastasectomy improves survival in patients with metastatic urothelial carcinoma. Anticancer Res 36(10):5557–5561

Muilwijk T, Akand M, Van der Aa F et al (2020) Metastasectomy of oligometastatic urothelial cancer: a single-center experience. Translat Androl Urol 9(3):1296–1305. https://doi.org/10.21037/tau-19-624CrossRef

Iyengar P, Wardak Z, Gerber DE et al (2018) Consolidative radiotherapy for limited metastatic non-small-cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 4(1):e173501. https://doi.org/10.1001/jamaoncol.2017.3501CrossRefPubMed

Wei Q, He H, Lv L et al (2020) The promising role of radiotherapy in the treatment of advanced or metastatic renal cell carcinoma: a narrative review. Translat Androl Urol 9(6):2821–2830. https://doi.org/10.21037/tau-20-1466CrossRef

10.

Ikeda M, Matsumoto K, Niibe Y et al (2011) The radiotherapy with methotrexate, vinblastine, doxorubicin, and cisplatin treatment is an effective therapeutic option in patients with advanced or metastatic bladder cancer. J Radiat Res 52 (5):674–679

11.

Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial. Lancet (London, England) 393(10185):2051–2058. https://doi.org/10.1016/S0140-6736(18)32487-5CrossRefPubMed

12.

Bentzen SM, Constine LS, Deasy JO et al (2010) Quantitative analyses of normal tissue effects in the clinic (QUANTEC): an introduction to the scientific issues. Int J Radiat Oncol Biol Phys 76(3 Suppl):S3–S9. https://doi.org/10.1016/j.ijrobp.2009.09.040CrossRefPubMedPubMedCentral

13.

Rouprêt M, Babjuk M, Burger M et al (2021) European association of urology guidelines on upper urinary tract urothelial carcinoma: 2020 update. Eur Urol 79(1):62–79. https://doi.org/10.1016/j.eururo.2020.05.042CrossRefPubMed

14.

Sfakianos JP, Gul Z, Shariat SF et al (2021) Genetic differences between bladder and upper urinary tract carcinoma: implications for therapy. Eur Urol Oncol 4(2):170–179. https://doi.org/10.1016/j.euo.2020.12.007CrossRefPubMed

15.

Esagian SM, Khaki AR, Diamantopoulos LN et al (2021) Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes. BJU Int 128(2):196–205. https://doi.org/10.1111/bju.15324CrossRefPubMed

16.

Audenet F, Isharwal S, Cha EK et al (2019) Clonal relatedness and mutational differences between upper tract and bladder urothelial carcinoma. Clin Cancer Res 25(3):967–976. https://doi.org/10.1158/1078-0432.CCR-18-2039CrossRefPubMed

17.

Li X, Li S, Chi Z et al (2021) Clinicopathological characteristics, prognosis, and chemosensitivity in patients with metastatic upper tract urothelial carcinoma. Urol Oncol 39(1):75.e71-75.e78. https://doi.org/10.1016/j.urolonc.2020.06.010CrossRef

18.

Liu M-Z, Gao X-S, Qin S-B et al (2021) Radiation therapy for nonmetastatic medically inoperable upper-tract urothelial carcinoma. Translat Androl Urol 10(7):2929–2937. https://doi.org/10.21037/tau-21-291CrossRef

19.

Abe T, Minami K, Harabayashi T et al (2020) Prognostic impact of local radiotherapy on metastatic urothelial carcinoma patients receiving systemic chemotherapy. Jpn J Clin Oncol 50(2):206–213. https://doi.org/10.1093/jjco/hyz152CrossRefPubMed

20.

Deng L, Liang H, Burnette B et al (2014) Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124(2):687–695. https://doi.org/10.1172/JCI67313CrossRefPubMedPubMedCentral

21.

Ngwa W, Irabor OC, Schoenfeld JD et al (2018) Using immunotherapy to boost the abscopal effect. Nat Rev Cancer 18(5):313–322. https://doi.org/10.1038/nrc.2018.6CrossRefPubMedPubMedCentral

22.

Brooks ED, Schoenhals JE, Tang C et al (2016) Stereotactic ablative radiation therapy combined with immunotherapy for solid tumors. Cancer J 22(4):257–266. https://doi.org/10.1097/PPO.0000000000000210CrossRefPubMedPubMedCentral

23.

Hiniker SM, Reddy SA, Maecker HT et al (2016) A prospective clinical trial combining radiation therapy with systemic immunotherapy in metastatic melanoma. Int J Radiat Oncol Biol Phys 96(3):578–588. https://doi.org/10.1016/j.ijrobp.2016.07.005CrossRefPubMedPubMedCentral

24.

An Y, Jiang W, Kim BYS et al (2017) Stereotactic radiosurgery of early melanoma brain metastases after initiation of anti-CTLA-4 treatment is associated with improved intracranial control. Radiother Oncol 125(1):80–88. https://doi.org/10.1016/j.radonc.2017.08.009CrossRefPubMed

25.

Shaverdian N, Lisberg AE, Bornazyan K et al (2017) Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. Lancet Oncol 18(7):895–903. https://doi.org/10.1016/S1470-2045(17)30380-7CrossRefPubMedPubMedCentral

26.

Chmura S, Winter KA, Robinson C et al (2021) Evaluation of safety of stereotactic body radiotherapy for the treatment of patients with multiple metastases: findings from the NRG-BR001 Phase 1 Trial. JAMA Oncol 7(6):845–852. https://doi.org/10.1001/jamaoncol.2021.0687CrossRefPubMedPubMedCentral

27.

Brooks ED, Chang JY (2019) Time to abandon single-site irradiation for inducing abscopal effects. Nat Rev Clin Oncol 16(2):123–135. https://doi.org/10.1038/s41571-018-0119-7CrossRefPubMed

28.

Palma DA, Olson R, Harrow S et al (2019) Stereotactic ablative radiotherapy for the comprehensive treatment of 4–10 oligometastatic tumors (SABR-COMET-10): study protocol for a randomized phase III trial. BMC Cancer 19(1):816. https://doi.org/10.1186/s12885-019-5977-6CrossRefPubMedPubMedCentral

29.

Sundahl N, Vandekerkhove G, Decaestecker K et al (2019) Randomized Phase 1 Trial of pembrolizumab with sequential versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma. Eur Urol 75(5):707–711. https://doi.org/10.1016/j.eururo.2019.01.009CrossRefPubMed

30.

Kim JK, Moon KC, Jeong CW et al (2017) Variant histology as a significant predictor of survival after radical nephroureterectomy in patients with upper urinary tract urothelial carcinoma. Urol Oncol https://doi.org/10.1016/j.urolonc.2017.02.010

31.

Mori K, Janisch F, Parizi MK et al (2020) Prognostic value of variant histology in upper tract urothelial carcinoma treated with nephroureterectomy: a systematic review and meta-analysis. J Urol 203(6):1075–1084. https://doi.org/10.1097/JU.0000000000000523CrossRefPubMed

Titel: Safety and efficacy of radiotherapy combined with chemotherapy for recurrent metastatic renal pelvic and ureteral carcinoma
verfasst von: Ming-Zhu Liu
Xiao-Ying Li
Feng Lyu
Xian-Shu Gao
Jia-Yan Chen
Yan Gao
Mu Xie
Xue-Ying Ren
Ming-Wei Ma
Publikationsdatum: 01.12.2024
Verlag: Springer Berlin Heidelberg
Erschienen in: World Journal of Urology / Ausgabe 1/2024
Print ISSN: 0724-4983
Elektronische ISSN: 1433-8726
DOI: https://doi.org/10.1007/s00345-023-04701-8

Neu im Fachgebiet Urologie

Patrone im Penis bringt Urologen in Gefahr

30.05.2024 Operationen am Penis Nachrichten

In Lebensgefahr brachte ein junger Mann nicht nur sich selbst, sondern auch das urologische Team, das ihm zu Hilfe kam: Er hatte sich zur Selbstbefriedigung eine scharfe Patrone in die Harnröhre gesteckt.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Fehlerkultur in der Medizin – Offenheit zählt!

28.05.2024 Fehlerkultur Podcast

Darüber reden und aus Fehlern lernen, sollte das Motto in der Medizin lauten. Und zwar nicht nur im Sinne der Patientensicherheit. Eine negative Fehlerkultur kann auch die Behandelnden ernsthaft krank machen, warnt Prof. Dr. Reinhard Strametz. Ein Plädoyer und ein Leitfaden für den offenen Umgang mit kritischen Ereignissen in Medizin und Pflege.

Update Urologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Safety and efficacy of radiotherapy combined with chemotherapy for recurrent metastatic renal pelvic and ureteral carcinoma